Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$110.29
▼ $4.57 (-4.0%)
Market data updated: 09/20 04:12 AM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
$11.92B
Day Range
$108.41 - $117.82
52-Week Range
$28.66 - $126.38
Beta
—
Next Earnings
02.11.2026
Support
$84.88
Resistance
$126.38
CORT is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+38.2% (1Y)
Strengths: 11/31 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Leverage risk
Debt/equity: 0.00
Risk
Biggest negative driver
DCF Fair Value
Estimated fair value: $29.71 vs. price $110.29 (-73.1%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
50
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
37
Quality
47
Value
33
Momentum
46
Risk
54
Sentiment
68
Fundamental
69
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage on Corcept Therapeutics has primarily focused on insider selling activity, with two separate reports noting significant share sales by company insiders worth approximately **$2.86 million** and **$6.46 million**, as disclosed in SEC filings. No other substantive corporate updates or major news events were found in the provided sources.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Corcept Therapeutics Incorporated. News trend score: 68. Reason: 5 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
46
🎯 Conviction (vs. Emotion)
37
Psychology
51
Fundamentals
69
Technical
46
Valuation
33
Extreme momentum, price far above its moving average, and a large premium over fair value.
The price rise has far outpaced the actual improvement in fundamental data.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+38%
Market Narrative
61
Fundamental Reality
37
Narrative Gap
+24
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
CORT’s psychology score (51) reflects a dominant *Euphoria* state, where detached optimism persists despite weak momentum (-6.2% ROC) and a 284% premium to DCF. Overconfidence (45) further suggests investors ignore fundamental divergence, prioritizing relative outperformance. The 22-point narrative gap (57 vs. 35) hints at exaggerated positive framing. Key question: Will traders sustain this disconnect as momentum remains negative, or will reality (e.g., earnings) force a re-evaluation?
Updated: 09/09/2026, 02:23 AM
What could change this?
👥 What the crowd believes
"Corcept Therapeutics Insider Sold Shares Worth $2,860,737"
"Corcept (CORT) reported earnings... stock down 1.2%"
📈 15D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 99/100
🔴 Weakest match
Thorstein Veblen — 22/100
🗣️ Why do they disagree?
Based on each investor's documented principles, the model estimates that Walter Bagehot sees strong liquidity and would likely view CORT as resilient, while Morgan Housel flags extreme volatility that would shake patient holders. The mid‑range scores from Burton Malkiel & John Bogle, Gerald Loeb, Jesse Livermore, and the cycle‑focused analysts suggest a mixed or moderate risk case, reflecting uncertainty rather than a clear buy or sell signal. Value‑oriented frameworks such as Benjamin Graham’s defensive and enterprising criteria, as well as Philip Fisher and Peter Lynch, rate the stock low, indicating concerns about valuation, safety margins, and growth quality. Conversely, growth‑centric and crowd‑behavior lenses like Charles Mackay, Thorstein Veblen, and Edgar Smith also produce modest scores, showing that the company does not meet their signatures for sustainable growth or a sound long‑term investment case.
Walter Bagehot
Lombard Street (1873)
🟢 99
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 84
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 57
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 53
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 50
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 49
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 46
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 44
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 42
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 34
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 34
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 31
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 30
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 28
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 22
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (3 bullish · 6 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
98.3%
Operating Margin
5.9%
Net Margin
13.1%
EBITDA Margin
—
ROE
15.4%
ROA
11.9%
ROIC
—
EPS
$0.95
Cash
$120.50M
Total Debt
—
Current Ratio
2.92
Debt/Equity
0.00
How is Fair Value calculated? →
Current Price
$110.29
Estimated Fair Value (DCF)
$29.71
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-73.1%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
24.3%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 24.3% | $176.18M | $161.63M |
| 2 | 18.8% | $209.33M | $176.19M |
| 3 | 13.4% | $237.34M | $183.27M |
| 4 | 7.9% | $256.18M | $181.48M |
| 5 | 2.5% | $262.58M | $170.66M |
Base FCF (last actual year)
$141.78M
Terminal Value
$4.14B
Present Value of Terminal Value
$2.69B
Enterprise Value
$3.56B
Net Debt
$0
Equity Value
$3.56B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$6.11
Tangible Book Value per Share (Tangible NAV)
$3.83
Sentiment based on basic keywords (not AI) — 5 positive, 13 neutral, 2 negative out of the last 20 articles.
Benzinga · 18.9.2026
Yahoo · 18.9.2026
Benzinga · 17.9.2026
ChartMill · 17.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
SeekingAlpha · 8.9.2026
Stocktwits · 4.9.2026
Yahoo · 4.9.2026
PR Newswire · 4.9.2026
Yahoo · 4.9.2026
Zacks · 4.9.2026
Yahoo · 4.9.2026
MT Newswires · 4.9.2026
MT Newswires · 4.9.2026
Yahoo · 2.9.2026
StockStory · 2.9.2026
SeekingAlpha · 31.8.2026
Yahoo · 28.8.2026
Zacks · 28.8.2026
Corcept Therapeutics Incorporated (CORT) currently has a StockIQ AI score of 50/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
CORT currently scores 50/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, CORT's estimated fair value is $29.71, which is 73.1% below the current price of $110.29. This is one valuation model among several signals in the fair-value category, not a price target.
CORT's technical score is 46/100, which currently reads as neutral — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Debt/equity: 0.00; Current ratio: 2.92; Price is above the 50-day average.
Based on the real signals StockIQ computed: Estimated fair value: $29.71 vs. price $110.29 (-73.1%); Operating margin is eroding over time; ATR: 4.5% of price.
StockIQ has no recorded dividend payment history for CORT.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 10 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Lyon Joseph Douglas | Tax Withholding in Shares | 2.9.2026 | 72 | -72 | $113.38 |
| Robb Gary Charles | Tax Withholding in Shares | 2.9.2026 | 91 | -91 | $113.38 |
| Vieira Roberto Wandenkolk | Open Market Sale | 2.9.2026 | 23,770 | -23,770 | $110.70 |
| Vieira Roberto Wandenkolk | Exercise of Derivative Securities | 2.9.2026 | 58,333 | +58,333 | $21.63 |
| Vieira Roberto Wandenkolk | Open Market Sale | 2.9.2026 | 5,621 | -5,621 | $114.58 |
| Vieira Roberto Wandenkolk | Open Market Sale | 2.9.2026 | 23,600 | -23,600 | $109.35 |
| Vieira Roberto Wandenkolk | Open Market Sale | 2.9.2026 | 974 | -974 | $112.40 |
| Vieira Roberto Wandenkolk | Open Market Sale | 2.9.2026 | 1,606 | -1,606 | $113.72 |
| Vieira Roberto Wandenkolk | Exercise of Derivative Securities | 2.9.2026 | 58,333 | -58,333 | — |
| Vieira Roberto Wandenkolk | Tax Withholding in Shares | 2.9.2026 | 102 | -102 | $113.38 |
| Vieira Roberto Wandenkolk | Open Market Sale | 2.9.2026 | 1,537 | -1,537 | $111.37 |
| Vieira Roberto Wandenkolk | Open Market Sale | 2.9.2026 | 1,225 | -1,225 | $115.44 |
| Mokari Atabak | Tax Withholding in Shares | 2.9.2026 | 102 | -102 | $113.38 |
| Maduck Sean | Tax Withholding in Shares | 2.9.2026 | 117 | -117 | $113.38 |
| Maduck Sean | Open Market Sale | 1.9.2026 | 11,730 | -11,730 | $113.94 |
| Maduck Sean | Grant/Award from Employer | 1.9.2026 | 150 | +150 | $113.38 |
| Lyon Joseph Douglas | Grant/Award from Employer | 1.9.2026 | 130 | +130 | $113.38 |
| Maduck Sean | Open Market Sale | 1.9.2026 | 2,281 | -2,281 | $115.61 |
| Mokari Atabak | Grant/Award from Employer | 1.9.2026 | 138 | +138 | — |
| Maduck Sean | Exercise of Derivative Securities | 1.9.2026 | 25,000 | -25,000 | — |
| Maduck Sean | Grant/Award from Employer | 1.9.2026 | 150 | +150 | — |
| Vieira Roberto Wandenkolk | Grant/Award from Employer | 1.9.2026 | 138 | +138 | $113.38 |
| Guyer William | Grant/Award from Employer | 1.9.2026 | 164 | +164 | $113.38 |
| Robb Gary Charles | Grant/Award from Employer | 1.9.2026 | 164 | +164 | — |
| Maduck Sean | Open Market Sale | 1.9.2026 | 10,989 | -10,989 | $114.71 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
9,399,154 shares short as of 2026-08-31 · vs. 9,819,732 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
60.7% of trading volume this week was short selling, vs. 72.2% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology